Agios pharma stock price

5 Mar 2020 On Wednesday, shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) marked $48.43 per share versus a previous $46.78 closing price. 24 Feb 2020 The forecasts give the Agios Pharmaceuticals Inc. stock a price target range of $80.00 on the higher side while at least one analyst think the 

Agios Pharma has an analyst consensus of Strong Buy, with a price target consensus of $66.71, a 33.4% upside from current levels. In a report issued on January 31, J.P. Morgan also reiterated a Buy rating on the stock. See today’s analyst top recommended stocks >> Fate Therapeutics (FATE) Agios Pharmaceuticals Shares Rise on Buyout Speculation Apr 10, 2018 · Shares of Agios Pharmaceuticals, Inc. AGIO rallied almost 10% on Apr 9 after speculations were rife that the company might be acquired by other big … AGIO Stock Quote | Agios Pharmaceuticals Research I hate to pit myself against another 2013 biopharma IPO but a billion dollar market cap for this outfit seems a little rich for me. The priniciple of inhibition of cell differentiation is interesting, and the partnership with Celgene is intriguing,…

AGIO Stock Price | Agios Pharmaceuticals Inc. Stock Quote ...

ALBO:NASDAQ CM Stock Quote - Albireo Pharma Inc ... Stock analysis for Albireo Pharma Inc (ALBO:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. NASDAQ:AGIO Agios Pharmaceuticals, Inc. Stock Analysis ... Summary quote, performance, and fundamental analysis for NASDAQ:AGIO Agios Pharmaceuticals, Inc. Agios Pharmaceuticals Market Cap | AGIO

Agios Upgraded As Anemia Drug Data Soothes Safety Concerns ...

Agios Pharma: Top Biotech Stock 2020 | Biotech Investments Oct 26, 2019 · Even more, we think that the current stock price of Agios represents an ideal opportunity to buy shares of this biotech pearl. Disclaimer. The purpose of the website www.biotech-investments.com and the Biotech Investments MAGAZINE is to provide persons interested in stock markets with financial information from the field of biotechnology. AGIO Stock Quote of Agios Pharmaceuticals - InvestorPlace Celgene buying out Agios would make sense but either way the company's work on cellular metabolism and gene deleting is interesting the bulls the most. Agios stock is a good buy on its own merits. Agios Pharmaceuticals Inc AGIO - Quotes, Financials, News ... Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases.

Agios Pharmaceuticals Market Cap | AGIO

Agios Pharmaceuticals Inc (AGIO) Quote | Morningstar Learn about AGIO with our data and independent analysis including price, star rating, valuation, dividends, and financials. Start a 14-day free trial to Morningstar Premium to unlock our take on AGIO. Is It Crazy To Buy Agios Pharmaceuticals Inc. (NASDAQ:AGIO ... Mar 04, 2020 · Agios Pharmaceuticals Inc. debt-to-equity ratio currently stands at 0.00, while its quick ratio hovers at 6.50 AGIO 52-week low price stands at $28.36 while its 52-week high price is $68.94. The company in its last quarterly report recorded -$1.60 earnings per share which is …

Agios Pharmaceuticals Shares Rise on Buyout Speculation ...

The Investor Relations website contains information about Agios Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. Investor Overview | Agios Pharmaceuticals, Inc. Agios Pharmaceuticals - Wikipedia In November 2019, Agios announced an underwritten public offering of 8,250,000 shares of common stock at a price of $31.00 per share which would result in approximately $256 million aggregate gross proceeds. Corporate governance. As of April 2017, Agios' CEO was David Schenkein. Agios Pharmaceuticals (NasdaqGS:AGIO) - Share price, News ... Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. AGIO - Agios Pharmaceuticals Summary, Stock ... - Benzinga

CAMBRIDGE, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced that it has priced an underwritten public offering of 8,250,000 shares of common stock at a price to the. 06 November 2019 Agios Announces Proposed Offering of Common Stock Agios Pharmaceuticals, Inc. - TheStreet AGIO Pharmacueticals (AGIO) Stock Up on Positive Drug Results. By Krishna Thakker. Jun 13, 2016 5:05 PM EDT. Agios Pharma, Concho Resources, Occidental, Sprouts and More. By TheStreet Staff. Investor Overview | Agios Pharmaceuticals, Inc.